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Introduction
Juvenile dermatomyositis (JDM) are potentially life-
threatening.
Objectives
We report 11 cases of severe JDM admitted in intensive
care unit (ICU) to determine their early severity signs
and outcomes.
Methods
We performed a retrospective study of cases of JDM
admitted in ICU in 2 pediatric rheumatology centers
(Paris, Toulouse) from 2005 to 2013, and compared
them to the JDM patients who did not require ICU.
Results
11/116 DMJ (9.3%) (8 girls and 3 boys, median age at diag-
nosis : 9.0± 3.1 years) were admitted in ICU for digestive
involvement (2 with digestive perforation after pulse corti-
costeroids) (4 patients), bradycardia (1 patient), cardiac
arrest (1 patient), hypoxemic pneumonia (1 patient), PRES
syndrome due to cyclosporine (1 patient), thrombotic
microangiopathy (TMA) (2 patients) and anaphylactic
shock due to Rituximab (1 patient). The incidence of
some clinical and biological manifestations differed from
severe patients to patients with mild JDM: hyponatremia
(9), hypoalbuminemia (9), generalized edema (6), anemia
(hemoglobin value <8 g/dL) (8), abdominal pain (7),
thrombocytopenia (platelet count : 100-150 x 109/L )(7).
The patients were treated by corticosteroids (11, compris-
ing 5 with pulse), intravenous immunoglobulins (7),
plasmapheresis (7), Rituximab (4) and cyclophosphamide
(2). One patient died in ICU from pneumocystosis ; 5 are
currently in complete remission and 5 in partial remission
with a mean follow-up duration of 4,7 years.
Conclusion
Generalized edema, digestive involvement (including
abdominal pain), thrombocytopenia (with TMA), hypona-
tremia and hypoalbuminemia seem to be early warning
signs of severe DMJ and should be identify to improve
prognosis. Our study suggests that severe DMJ should
early benefit from plasmapheresis ± Rituximab, whereas
pulse corticosteroids might contribute to digestive perfora-
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